|
|
罗沙司他联合促红细胞生成素治疗血液透析促红细胞生成素低反应性贫血患者1例
|
Abstract:
肾性贫血是肾衰竭患者最常见的并发症之一，本文报告了1例维持性血液透析患者治疗18个月后发生促红细胞生成素低反应性贫血，予以促红细胞生成素加量或换用低氧诱导因子脯氨酰羟化酶抑制剂(罗沙司他)治疗均不能纠正，在联合使用促红细胞生成素和罗沙司他治疗后患者的贫血情况得到了显著改善。
Renal anemia is a common complication in patients with renal failure. In this paper, we report a case of erythropoietin hyporesponsive anemia in a maintenance hemodialysis patient after 18 months of treatment, which was not corrected by erythropoietin dosing or by switching to hypoxiainducing factor prolyl hydroxylase inhibitor (Roxadustat) therapy. The patient’s anemia improved significantly after combined treatment with erythropoietin and Roxadustat.
| [1] | 中国医师协会肾脏内科医师分会肾性贫血指南工作组. 中国肾性贫血诊治临床实践指南[J]. 中华医学杂志, 2021, 6(20): 1463-1502. |
| [2] | 中华医学会肾脏病学分会肾性贫血诊断和治疗共识专家组. 肾性贫血诊断与治疗中国专家共识(2018修订版) [J].中华肾脏病杂志, 2018, 34(11): 860-866. |
| [3] | Zhang, L., Wang, F., Wang, L., et al. (2012) Prevalence of Chronic Kidney Disease in China: A Cross-Sectional Survey. The Lancet, 379, 815-822. https://doi.org/10.1016/S0140-6736(12)60033-6 |
| [4] | Zuo, L., Wang, M., Hou, F., et al. (2016) Anemia Manage-ment in the China Dialysis Outcomes and Practice Patterns Study. Blood Purification, 42, 33-43. https://doi.org/10.1159/000442741 |
| [5] | Ursula, V., Soraya, A., Almudena, V., et al. (2011) Factors Related to the Absence of Anemia in Hemodialysis Patients. Blood Purification, 32, 69-74. https://doi.org/10.1159/000323095 |
| [6] | Rafiou, A., Anna, M., Regina, G., et al. (2018) Inhibition of Fibroblast Growth Factor 23 (FGF23) Signaling Rescues Renal Anemia. FASEB Journal, 32, 3752-3764. https://doi.org/10.1096/fj.201700667R |
| [7] | 董建华, 范文静, 吴边, 等. 罗沙司他治疗血液透析患者红细胞生成素低反应性贫血的疗效观察[J]. 肾脏病与透析肾移植杂志, 2021, 30(3): 211-216. |
| [8] | Qie, S., Jiao, N., Duan, K., et al. (2021) The Efficacy and Safety of Roxadustat Treatment for Anemia in Patients with Kidney Disease: A Me-ta-Analysis and Systematic Review. International Urology and Nephrology, 53, 985-997.
https://doi.org/10.1007/s11255-020-02693-7 |
| [9] | 赵娜, 郭一丹, 赵春霞, 等. 重组人促红素联合左卡尼汀对老年血液透析患者肾性贫血治疗效果及氧化应激的影响[ J]. 临床误诊误治, 2021, 34(4): 33-38. |
| [10] | 郑可, 李雪梅, 慢性肾脏病贫血与心血管疾病[J]. 中国实用内科杂志, 2020, 40(11): 903-907. |
| [11] | Wu, C.J., Chen, C.Y., Lai, T., et al. (2017) The Role of Indoxyl Sulfatein Renal Anemia in Patients with Chronic Kidney Disease. Oncotarget, 8, 83030-83037. https://doi.org/10.18632/oncotarget.18789 |
| [12] | Alves, M.T., Vilaca, S.S., Md, C., et al. (2015) Re-sistance of Dialyzed Patients to Erythropoietin. Revista Brasileira de Hematologia e Hemoterapia, 37, 190-197. https://doi.org/10.1016/j.bjhh.2015.02.001 |
| [13] | Zhou, Q.G., Jiang, J.P., Wu, S.J., et al. (2012) Current Pattern of Chinese Dialysis Units: A Cohort Study in a Representative Sample of Units. Chinese Medical Journal (Engl), 125, 3434-3439. |
| [14] | Li, Y., Shi, H., Wang, W.M., et al. (2016) Prevalence, Awareness, and Treatment of Anemia in Chi-nese Patients with Nondialysis Chronic Kidney Disease: First Multicenter, Cross-Sectional Study. Medicine (Baltimore), 95, e3872.
https://doi.org/10.1097/MD.0000000000003872 |
| [15] | Wang, Y., Dang, Z.H., Gan, L.Y., et al. (2021) The Influ-ence of Altitude on Erythropoietin Resistance Index in Maintenance Hemodialysis Patients: Data from Tibetan Plateau. Blood Purification, 50, 364-369.
https://doi.org/10.1159/000510997 |
| [16] | Vander, P.K., Braam, B., Jie, K.E., et al. (2008) Mechanisms of Disease: Erythropoietin Resistance in Patients with Both Heart and Kidney Failure. Nature Clinical Practice Nephrology, 4, 47-57. https://doi.org/10.1038/ncpneph0655 |
| [17] | Macdougall, I.C., Cooper, A.C. (2002) Erythropoietin Resistance: The Role of Inflammation and Pro-Inflammatory Cytokines. Nephrology Dialysis Transplantation, 17, 39-43. https://doi.org/10.1093/ndt/17.suppl_11.39 |
| [18] | Wong, H.S., Chang, C.M., Kao, C., et al. (2017) V-J Combina-tions of T-Cell Receptor Predict Responses to Erythropoietin in End-Stage Renal Disease Patients. Journal of Biomedical Science, 24, 43-51.
https://doi.org/10.1186/s12929-017-0349-5 |
| [19] | Provenzano, R., et al. (2016) Roxadustat (FG-4592) versus Epo-etin Alfa for Anemia in Patients Receiving Maintenance Hemodialysis: A Phase 2, Randomized, 6- to 19-Week, Open-Label, Actinve-Comparator, Dose-Ranging, Safety and Exploratory Efficacy Study. American Journal of Kidney Diseases, 67, 912-924.
https://doi.org/10.1053/j.ajkd.2015.12.020 |
| [20] | Chen, N., Hao, C., Liu, B.C., et al. (2019) Roxadustat Treatment for Anemia in Patients Undergoing Long-Term Dialysis. The New England Journal of Medicine, 381, 1011-1022. https://doi.org/10.1056/NEJMoa1901713 |
| [21] | Cygulska, K., Wejner, M.P., Plewka, M., et al. (2019) Roxadustat: Another Drug That Causes Pulmonary Hypertension? Report of First Human Case. Polish Archives of Internal Medicine, 129, 344-345.
https://doi.org/10.20452/pamw.4445 |
| [22] | Nishide, S., Matsunaga, S., Shiota, M., et al. (2019) Controlling the Phenotype of Tumor-Infiltrating Macrophages via the PHD-HIF Axis Inhibits Tumor Growth in a Mouse Model. iSci-ence, 19, 940-954.
https://doi.org/10.1016/j.isci.2019.08.033 |
| [23] | Tang, D., Zhang, J., Yan, T., et al. (2018) FG-4592 Accelerates Cutaneous Wound Healing by Epidermal Stem Cell Activation via HIF-1α Stabilization. Cellular Physiology and Bio-chemistry, 46, 2460-2470.
https://doi.org/10.1159/000489652 |
| [24] | Bartels, K., Grenz, A., Eltzschig, H.K. (2013) Hypoxia and Inflammation Are Two Sides of the Same Coin. Proceedings of the National Academy of Sciences of the United States of America, 110, 18351-18352.
https://doi.org/10.1073/pnas.1318345110 |
| [25] | 高燕, 黄恺. 维持性血液透析过程中患者血压变异性及影响因素研究[J]. 中国现代医生, 2014, 52(19): 15-18. |
| [26] | 陈秀兰, 曾英彤, 等. 左卡尼汀治疗维持性血液透析患者肾性贫血的Meta分析[J]. 分子影像学杂志, 2015, 38(4): 376-381. |
| [27] | 周凌辉, 程翱, 等. 不同种类促红细胞生成素治疗维持性血液透析患者肾性贫血的效果[J]. 中外医学研究, 2017, 15(8): 1-3. |
